Long term this company has great things outside of Trimesta so the degree of risk is minimized.
Seel made a point and maybe it was on the board but regardless of positive or negative results for Trimesta they will be discussed in order advance scientific discovery. I do agree that one cannot predict results will be positive and this is a very stringent trial design so that makes it tougher to say one way or the other. Just based on patient type and results in earlier study's with this patient type I feel good about what will be released. But that is just my opinion and I'm not a statician nor am I claiming to be an expert on looking at clinical studies.
At any rate long term I will be good due to the pipeline in development and that allows me more confidence to see the results laid out for Trimesta.
Dr V will be presenting top line data in one presentation and in another presentation she will discuss the MOA of Trimesta. There will be a great deal of info to look at...
Market Data 
Markets 
AI
